Company news
ImmuPharma plc news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Update: FDA confirms 4 Dec for Type 'A' meeting
November 20, 2020
Total Share Capital Notification - Replacement
November 18, 2020
Update on submission to the FDA
November 10, 2020
Share Subscription into Incanthera plc
September 29, 2020
Repayment of Convertible Security
September 22, 2020
Director/PDMR Shareholding / TR -1
September 8, 2020
Placing - update; related party transaction)
September 7, 2020
Placing to raise £6.5 million
September 2, 2020
FDA submission for Special Protocol Assessment
July 27, 2020
2020 Agm - all resolutions passed
June 18, 2020
Strat. invts from 2 specialist US h'care investors
June 11, 2020
Change of Registered Office Address
June 5, 2020
Notification of Change of AGM Venue
June 2, 2020
Efforts in fight vs Covid-19 with Lupuzor; Ureka
May 14, 2020
Audited Report & Accounts published on website
April 30, 2020
IMM live on Investor Meet Company platform 7 April
April 6, 2020
£1.5m Subscrip'n to fund R&D pipeline- replacement
March 30, 2020
Incanthera plc - Admission to trading on NEX
February 28, 2020
Incanthera announces Rule 23 Notice re NEX listing
February 17, 2020
Update on the Avion Agreement
February 6, 2020
Admission today to trading on Euronext Growth
December 19, 2019
Publication of Information Note (Euronext Growth)
December 17, 2019
Dual Listing on Euronext Growth Brussels
December 13, 2019
Share Price Volatility
December 11, 2019
ImmuPharma to present at Biotech showcaset 2020
December 3, 2019
TR-1: notification of major holdings
December 2, 2019
Licence Agreement for Lupuzor with Avion in US
November 28, 2019
Interim Results Announcement
September 30, 2019
2019 Annual General Meeting
June 27, 2019
Subscription to raise £2.66 million
June 26, 2019
Final results
May 24, 2019
Corporate Update - Replacement
May 7, 2019
Update on Nucant Cancer Programme
April 1, 2019
Technology review published-Nature Communications
February 26, 2019
Clinical Development Collaboration with Incanthera
December 31, 2018
Appointment of Nominated Adviser
December 17, 2018
Update on Corporate Activities
December 7, 2018
Nominated Adviser Status
November 1, 2018
Appointment of Joint Brokers
September 19, 2018
Results of CIDP Pre-Clinical Data
June 14, 2018
Notice of AGM & Posting of Annual Report
June 6, 2018
Update on Pivotal Phase III Trial of Lupuzor
May 29, 2018
Topline results of Lupuzor Pivotal Phase III Trial
April 17, 2018
Appointment of Joint Broker
March 28, 2018
Lupuzor Pivotal Phase III Study Update
March 23, 2018
AIM Notice (17)
March 5, 2018
London Investor Evening
February 15, 2018
Successful Placing to Raise £10 Million
January 24, 2018
Completion of LupuzorT Pivotal Phase III Study
January 18, 2018
Last patient completes dosing in LupuzorT Trial
December 21, 2017
Calls
Decks
- Investor Presentation (April 2020)
Investor deck · 15 slides · April 2020